Format

Send to

Choose Destination
Pediatr Blood Cancer. 2013 Jun;60(6):957-63. doi: 10.1002/pbc.24420. Epub 2012 Dec 19.

Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.

Author information

1
University of Colorado School of Medicine, The University of Colorado Cancer Center and Children's Hospital Colorado, Aurora, Colorado, USA. stephen.hunger@childrenscolorado.org

Abstract

Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/µl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

PMID:
23255467
PMCID:
PMC4045498
DOI:
10.1002/pbc.24420
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center